The article focuses on the treatment of atrial fibrillation by the oral anticoagulant drugs. It is discussed that clinical trials were conducted to investigate the efficacy and safety of Dabigatran, Rivaroxaban and Apixaban. It is also stated that anticoagulants provide an alternative treatment to vitamin k antagonist in preventing stroke and systemic embolism.